Nirvana Life Sciences Inc.
NIRV
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 63.95% | 84.89% | 50.70% | 102.30% | 39.95% |
| Total Depreciation and Amortization | -- | -- | -73.37% | -47.06% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -39.94% | -100.06% | -73.92% | -27,150.00% | 5,533.33% |
| Change in Net Operating Assets | -91.12% | 66.12% | 264.17% | -35.33% | -62.38% |
| Cash from Operations | 59.54% | 98.98% | 91.52% | 65.76% | 40.28% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 176.47% | -33.75% | 113.90% | -91.45% | -77.22% |
| Total Debt Repaid | -- | -- | -- | -- | -100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.82% | -96.22% | -94.01% | -91.33% | -39.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.32% | -96.31% | -114.75% | -336.36% | 41.94% |
